Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MRGPRX4 | Q96LA9 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | F2 | P00734 | 1/20 | 0.39 |
| ▸ | F10 | P00742 | 1/20 | 0.39 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10000341 | 0.91 | LMNA (0.40) | HPGDLMNAMRGPRX4MEN1KMT2A | |
| SCHEMBL13754822 | 0.85 | F2 (0.43) | MEN1KMT2ASMN1; SMN2F2F10 | |
| SCHEMBL3132629 | 0.80 | LMNA (0.62) | HPGDLMNAMRGPRX4MEN1KMT2A | |
| SCHEMBL13815331 | 0.80 | F2 (0.39) | HPGDLMNAMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL986790 | 0.80 | TSHR (0.48) | HPGDLMNAMEN1KMT2AF2 | |
| SCHEMBL4151119 | 0.75 | PSEN1 (0.47) | HPGDLMNASMN1; SMN2KDM4EMAPT | |
| SCHEMBL3664509 | 0.74 | KDM4E (0.57) | HPGDKMT2AF2F10PRSS1 | |
| SCHEMBL13754824 | 0.74 | CYP1A2 (0.47) | LMNAMEN1KMT2AF2F10 | |
| SCHEMBL2177575 | 0.74 | MAOB (0.51) | HPGDLMNAMRGPRX4KDM4EMAPT | |
| SCHEMBL13754821 | 0.73 | F2 (0.39) | MEN1KMT2AF2F10PRSS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8124767-B2 | Luminescence biotin-transition metal complex conjugate, and method of amplifying signal using the same | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2012-02-28 | — | — | US | disclosed |
| US-8124767-B2 | Luminescence biotin-transition metal complex conjugate, and method of amplifying signal using the same | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2012-02-28 | — | — | US | disclosed |
| US-20090209048-A1 | Luminescence Biotin-Transition Metal Complex Conjugate, and Method of Amplifying Signal Using the Same | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2009-08-20 | — | — | US | disclosed |
| US-20090209048-A1 | Luminescence Biotin-Transition Metal Complex Conjugate, and Method of Amplifying Signal Using the Same | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2009-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090209048-A1 | Luminescence Biotin-Transition Metal Complex Conjugate, and Method of Amplifying Signal Using the Same | BTD, HLCS, BPGM | HPGD 1708/4885LMNA 590/4885MRGPRX4 4278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.